AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01268-06v1
51/3/1078    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, R. E.
Right arrow Articles by Kontoyiannis, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, R. E.
Right arrow Articles by Kontoyiannis, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1078-1081, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01268-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pretreatment with Empty Liposomes Attenuates the Immunopathology of Invasive Pulmonary Aspergillosis in Corticosteroid-Immunosuppressed Mice{triangledown}

Russell E. Lewis,1,2* Georgios Chamilos,1 Randall A. Prince,1,2 and Dimitrios P. Kontoyiannis1,2

College of Pharmacy, University of Houston, Houston, Texas,1 Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas2

Received 10 October 2006/ Returned for modification 30 November 2006/ Accepted 17 December 2006


   ABSTRACT
Top
 Abstract
Text
 References
 
In a nonneutropenic murine model of invasive pulmonary aspergillosis, pretreatment with empty liposomes (E-lipo) was nearly as effective as 10 mg/kg of body weight liposomal amphotericin B and superior to 1 mg/kg amphotericin B deoxycholate. The beneficial immunomodulatory properties of E-lipo appear to compensate for their lack of direct antifungal activity.


   TEXT
Top
 Abstract
 Text
References
 
The pathology of invasive pulmonary aspergillosis (IPA) varies considerably between neutropenic and nonneutropenic hosts (2, 5, 9, 16). Experimental models of IPA have demonstrated that, in the setting of persistent neutropenia, damage to the lung is mediated by angioinvasive growth of hyphae leading to hemorrhage, thrombosis, and tissue necrosis with eventual fungal dissemination (2, 9). Histologically, minimal inflammatory exudates are observed in infected animals despite extensive fungal burden; however, high concentrations of tumor necrosis factor alpha (TNF-{alpha}) and interleukin-10 (IL-10) can be detected in the bronchial alveolar lavage fluid (BALF) (2). Antifungals such as amphotericin B (AMB), which effectively inhibit hyphal growth, can significantly prolong the survival of neutropenic animals with IPA (2, 5). In contrast, the pathogenesis of IPA in corticosteroid-immunosuppressed animals without neutropenia is characterized by an exuberant, dysregulated polymorphonuclear leukocyte (PMN)-mediated inflammatory response in the lung, low or undetectable concentrations of TNF-{alpha} or IL-10 in the BALF, few angioinvasive hyphae, and surprisingly minimal efficacy of AMB treatment (2, 5, 9). Consequently, control of a dysregulated exuberant host inflammatory response may be as critical as antifungal activity for animal survival in the setting of intensive corticosteroid immunosuppression (2, 8, 9).

Beyond their useful role as drug carriers, liposomes are known to have potent immunomodulating effects in phagocytic cells (3, 10, 14). Specifically, exposure to liposomes ex vivo can stimulate nonoxidative killing mechanisms in PMNs required for damaging Aspergillus sp. hyphae while minimizing release of reactive oxygen species and collagenases that damage the lung (3, 4, 6, 11). Hence, incorporation of AMB into a liposome may reduce the collateral inflammatory pathology of the drug while maintaining its antifungal efficacy. We hypothesized that the immunomodulatory properties of empty liposomes alone (without drug) may be sufficient to control the immunopathogenesis of IPA in corticosteroid-immunosuppressed mice with IPA. To test this hypothesis, we compared patterns of fungal burden clearance and inflammation, animal survival, and effectiveness of ex vivo PMN hyphal killing in corticosteroid-immunosuppressed mice treated with AMB-deoxycholate (AMB-d), liposomal amphotericin B (L-AMB), or empty liposomes.

(This work was presented in part at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16 to 19 December 2005).

Eight-week-old female BALB/c mice (18 to 25 g) (Charles River Laboratories) were immunosuppressed with 10-mg intraperitoneal injections of cortisone acetate (Sigma, St. Louis, MO) suspended in phosphate-buffered saline (PBS) plus 0.5% Tween 20 at 4 days, 1 day prior to inoculation. Mice were then inoculated intranasally with a 50-µl droplet containing 2.5 x 106 A. fumigatus 293 conidia suspended in PBS under nebulized 6% isoflurane for oxygen anesthesia as previously described (13, 19).

To ensure that the drug was available in the lung tissue at the time of infection, antifungal therapy was administered 72 h prior to inoculation and continued daily until day +3 after inoculation. AMB-d (1 mg/kg of body weight) (Amerisource-Bergan, Chesterbrook, PA), L-AMB (10 mg/kg) (Ambisome; Gilead Sciences, Inc., Foster City, CA), empty liposomes (Gilead Sciences) diluted in sterile 5% dextrose water (D5W), or D5W alone (control) was administered once daily by lateral tail vein injection. The final concentration of empty liposomes administered to mice was similar to the liposome concentration in the L-AMB injection.

At consecutive time points after inoculation (baseline, 24 h, and 72 h), five infected mice were euthanized by CO2 narcosis. Blood was immediately collected (1 ml) by cardiac puncture into heparinized syringes for isolation of PMNs, and lungs were harvested for determination of Aspergillus fumigatus fungal burden by quantitative real-time PCR as previously described (7, 18). We observed clear differences in the pattern of lung fungal burden between the treatment groups during the course of infection (Fig. 1A). In contrast to the control and AMD-d-treated animals, decreases in A. fumigatus lung fungal burden were observed only in the L-AMB- and empty-liposome-treated animals, with maximal –1.6 and –0.8 log10 changes in lung fungal burden, respectively, 72 h after inoculation. Differences in fungal clearance between the three treatment groups were confirmed by histology (Fig. 1B). The lungs of cortisone-immunosuppressed mice treated with AMB-d demonstrated progression to large foci of pneumonia with hyphal growth that was not observed to the same degree in L-AMB- and empty-liposome-pretreated animals.


Figure 1
View larger version (84K):
[in this window]
[in a new window]

  		FIG. 1. Pretreatment with L-AMB or empty liposomes, but not AMB-d, is associated with enhanced fungal clearance, survival, and reduced lung injury in corticosteroid-immunosuppressed mice with IPA. Control, 5% dextrose water; empty, empty liposomes. AMB-d was given at 1 mg/kg, and L-AMB was given at 10 mg/kg. A) Lung fungal burden versus time. Each datum point plus error bar represents the mean plus standard error of the mean of the A. fumigatus lung fungal burden of five mice versus time (hours) determined by real-time quantitative PCR (qPCR). Fungal burden is reported in A. fumigatus conidial equivalents (CE) of DNA. Fungal burdens at 72 h in each treatment group were compared by analysis of variance with Tukey's post hoc comparison. B) Lung histopathology. Shown are Grocott's methamine silver nitrate stains of lungs harvested at baseline and at 24 and 72 h after inoculation. Baseline (time zero) conidia are visible in the lung in all treatment groups. AMB-d-treated animals exhibit bronchiolitis with onset of conidium germination (24 h) that progresses to diffuse pneumonia at 72 h and extensive hyphal invasion despite treatment with AMB-d. L-AMB-treated animals display focal bronchiolitis, without substantial hyphal invasion at 72 h. Animals treated with empty liposomes exhibit focal bronchiolitis and evidence of containment of A. fumigatus hyphal invasion within infiltrates at 72 h. C) Survival curves of empty-liposome- and AMB-d-pretreated mice. Groups of 10 mice were immunosuppressed with either cortisone alone or cortisone plus cyclophosphamide and inoculated with 2.5 x 106 A. fumigatus conidia. Data are presented as Kaplan-Meier survival curves and were compared by means of log rank.

 
In "proof-of-principle" survival experiments, groups of 10 mice were immunosuppressed and inoculated as described above and pretreated with either empty liposomes or AMB-d. A third group of animals were administered intraperitoneal cyclophosphamide at 100 mg/kg in conjunction with cortisone at day 4 and day 1 during the pretreatment phase with empty liposomes. Pretreatment with empty liposomes significantly prolonged the survival of cortisone-immunosuppressed mice but not mice immunosuppressed with cortisone plus cyclophosphamide until 5 days after inoculation (hazard ratio [HR], 0.06; 95% confidence interval [CI], 0.015 to 0.23; P = 0.0024) (Fig. 1C). Survival was significantly improved by empty-liposome pretreatment in comparison with AMB-d pretreatment in corticosteroid-immunosuppressed mice with IPA (HR, 0.036; 95% CI, 0.15 to 0.89; P = 0.035).

Peripheral PMNs from each mouse were isolated from heparinized blood by dextran sedimentation (Amersham Biosciences, Uppsala, Sweden) and centrifugation over a Ficoll-Hypaque gradient (Sigma) to test their capacity to damage unopsonized A. fumigatus 293 hyphae (17). Hyphae were generated from cultures of 1 x 105 A. fumigatus 293 conidia grown for 16 h in endotoxin-free RPMI 1640 plus 10% fetal calf serum. After resuspension in fresh culture medium, hyphae were exposed to PMNs (1:1 ratio) for 60 min at 37°C in 5% CO2. PMNs were then hypotonically lysed, and hyphal viability was determined by the 2,3-bis {2-methyloxy-4-nitro-5-[(sulfenylamino)carbonyl]-2H-tetrazolium-5-carboxanilide} (XTT) assay (1). PMNs harvested from control, immunosuppressed mice demonstrated minimal capacity (≤5%) to damage A. fumigatus hyphae (Fig. 2). However, pretreatment with AMB-d, L-AMB, or empty liposomes enhanced baseline PMN ability to damage A. fumigatus hyphae (18.7% ± 4%, 44.7% ± 4%, and 32% ± 3%, respectively; P = 0.03 for L-AMB versus control), and this enhancement was maintained in L-AMB- or empty-liposome-treated animals for 72 h.


Figure 2
View larger version (12K):
[in this window]
[in a new window]

  		FIG. 2. Ex vivo peripheral PMN killing activity against A. fumigatus hyphae is enhanced by AMB-d, L-AMB, and empty-liposome pretreatment. Shown are baseline data (A) and data obtained 24 h (B) and 72 h (C) following intranasal inoculation with 2.5 x 106 A. fumigatus conidia in cortisone-immunosuppressed BALB/c mice. The degree of hyphal killing was determined by the XTT assay. Control, 5% dextrose water; empty, empty liposomes. AMB-d was given at 1 mg/kg, and L-AMB was given at 10 mg/kg. Percent killing is determined in relation to parallel A. fumigatus controls not exposed to PMN. Each bar represents the mean ± standard deviation of PMN killing results from three different mice.

 
In conclusion, we demonstrated that pretreatment of intensively corticosteroid-immunosuppressed mice with empty liposomes could positively influence the immunopathogenesis of IPA by enhanced fungal clearance, reduced lung injury, and improved survival. Direct modulation of key innate immune effector cells (i.e., PMNs), possibly through intracellular pattern recognition receptors (i.e., Toll-like receptor 4) (3, 4, 12, 15), may account for the efficacy of the empty liposomes despite their inherent lack of antifungal activity.


   ACKNOWLEDGMENTS
 
Animals used in this study were cared for in accordance with the highest standards for humane and ethical care as approved by the institutional animal care and use committee.

Support was provided by The University of Texas M. D. Anderson Faculty E. N. Cobb Scholar Award Research Endowment (to D.P.K.) and the National Institutes of Health (core grant 16672 to the University of Texas M. D. Anderson Cancer Center Animal Care Unit). R.E.L. and D.P.K. receive research support and consultancy fees from Merck & Co., Pfizer, Astellas, Enzon, and Schering-Plough. R.A.P. receives research support from Merck & Co., Pfizer, Ortho McNeil, and Enzon.

We thank John Perfect for his helpful suggestions, Gilead Sciences, Inc., for the empty liposomes, and the Woods Hole Molecular Mycology Course (R.E.L.) for instruction on techniques that were used in this study.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Clinical Sciences and Administration, The University of Houston College of Pharmacy, Texas Medical Center Campus, 1441 Moursund St., Houston, TX 77030. Phone: (713) 795-8326. Fax: (713) 795-8383. E-mail: rlewis{at}uh.edu. Back

{triangledown} Published ahead of print on 28 December 2006. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Akpogheneta, O., C. Gil-Lamaignere, A. Maloukou, and E. Roilides. 2003. Antifungal activity of human polymorphonuclear and mononuclear phagocytes against non-fumigatus Aspergillus species. Mycoses 46:77-83.[CrossRef][Medline]
  2. Balloy, V., M. Huerre, J. P. Latgé, and M. Chignard. 2005. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73:494-503.[Abstract/Free Full Text]
  3. Bellocchio, S., R. Gaziano, S. Bozza, G. Rossi, C. Montagnoli, K. Perruccio, M. Calvitti, L. Pitzurra, and L. Romani. 2005. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55:214-222.[Abstract/Free Full Text]
  4. Bellocchio, S., S. Moretti, K. Perruccio, F. Fallarino, S. Bozza, C. Montagnoli, P. Mosci, G. B. Lipford, L. Pitzurra, and L. Romani. 2004. TLRs govern neutrophil activity in aspergillosis. J. Immunol. 173:7406-7415.[Abstract/Free Full Text]
  5. Berenguer, J., M. C. Allende, J. W. Lee, K. Garrett, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am. J. Respir. Crit. Care Med. 152:1079-1086.[Abstract]
  6. BitMansour, A., and J. M. Brown. 2002. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J. Infect. Dis. 186:134-137.[CrossRef][Medline]
  7. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.[Abstract/Free Full Text]
  8. Casadevall, A., and L. A. Pirofski. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1:17-24.[CrossRef][Medline]
  9. Duong, M., N. Ouellet, M. Simard, Y. Bergeron, M. Olivier, and M. G. Bergeron. 1998. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J. Infect. Dis. 178:1472-1482.[CrossRef][Medline]
  10. Eierman, D. F., M. Yagami, S. M. Erme, S. R. Minchey, P. A. Harmon, K. J. Pratt, and A. S. Janoff. 1995. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc. Natl. Acad. Sci. USA 92:2815-2819.[Abstract/Free Full Text]
  11. Francis, P., J. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. A. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169:356-368.[Medline]
  12. Hayashi, F., T. K. Means, and A. D. Luster. 2003. Toll-like receptors stimulate human neutrophil function. Blood 102:2660-2669.[Abstract/Free Full Text]
  13. Lewis, R. E., and N. P. Wiederhold. 2005. Murine model of invasive aspergillosis. Methods Mol. Med. 118:129-142.[Medline]
  14. Rao, M., and C. R. Alving. 2000. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Delivery Rev. 41:171-188.[CrossRef][Medline]
  15. Razonable, R. R., M. Henault, L. N. Lee, C. Laethem, P. A. Johnston, H. L. Watson, and C. V. Paya. 2005. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 49:1617-1621.[Abstract/Free Full Text]
  16. Stephens-Romero, S. D., A. J. Mednick, and M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73:114-125.[Abstract/Free Full Text]
  17. Tsuda, Y., H. Takahashi, M. Kobayashi, T. Hanafusa, D. N. Herndon, and F. Suzuki. 2004. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 21:215-226.[CrossRef][Medline]
  18. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.[CrossRef][Medline]
  19. Wiederhold, N. P., V. H. Tam, J. Chi, R. A. Prince, D. P. Kontoyiannis, and R. E. Lewis. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, March 2007, p. 1078-1081, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01268-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01268-06v1
51/3/1078    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, R. E.
Right arrow Articles by Kontoyiannis, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, R. E.
Right arrow Articles by Kontoyiannis, D. P.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS